ImageneBio (IMA) AI Stock Analysis

• Market Cap: $149.83M
• Dividend Yield: N/A
• Average Volume (3M): 23.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.76
• Revenue Growth: -100.00%
• EPS Growth: 55.32%
• Country: US
• Employees: 10
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 11,181,676
• 10 Day Avg. Volume: 9,234
• 30 Day Avg. Volume: 23,297
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.17
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: ―

Ikena Oncology's overall stock score of 41.2 reflects significant challenges in financial performance, including declining revenues and negative cash flow, which weigh heavily on the score. Technical analysis shows lackluster momentum, while the valuation is unattractive due to negative earnings. Improvements in revenue generation and profitability are crucial for a better financial outlook.

Positive Factors

Merger Benefits

The merger with Inmagene Biopharmaceuticals is expected to provide the combined company with an estimated $175 million in cash to support development of the anti-OX40 antibody, IMG-007.

Product Potential

IMG-007 has shown comparable efficacy to other OX40 therapies in development in atopic dermatitis, with a more favorable safety profile due to its non–T-cell-depleting design.

Negative Factors

Shareholder Impact

Following the merger, current Ikena shareholders will own approximately 34.8% of the combined company, suggesting a combined company value of less than $300 million and enterprise value of below $120 million.

ImageneBio Business Overview & Revenue Model

Company Description

Ikena Oncology (IKNA) is a biopharmaceutical company focused on developing innovative cancer therapies. Operating within the healthcare and biotechnology sectors, Ikena leverages a deep understanding of cancer biology to create targeted oncology treatments. The company's core products are centered around its proprietary platform aimed at addressing immune-mediated and genetic drivers of cancer, with a pipeline that includes both clinical and preclinical stage drug candidates designed to improve patient outcomes.

How the Company Makes Money

Ikena Oncology makes money primarily through the development and commercialization of its proprietary drug candidates. The company generates revenue through partnerships and collaborations with other pharmaceutical companies, which may include milestone payments, research funding, and potential royalties on successfully developed and marketed drugs. Additionally, Ikena may earn income by out-licensing its drug candidates or technology platforms to other firms within the pharmaceutical industry. The company's revenue is also influenced by its ability to advance its drug candidates through clinical trials, obtain regulatory approvals, and successfully launch products into the market.

ImageneBio Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

ImageneBio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 13.36
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMA, the sentiment is Negative. The current price of 13.36 is below the 20-day moving average (MA) of 14.35, below the 50-day MA of 15.43, and below the 200-day MA of 16.50, indicating a bearish trend. The MACD of -0.60 indicates Positive momentum. The RSI at 36.31 is Neutral, neither overbought nor oversold. The STOCH value of 8.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMA.

ImageneBio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.33	-41.57%	2.23%	23.26%	-2.03%
DTIL	51 Neutral	$57.76M	2.40	-143.89%	―	-98.56%	-347.81%
BYSI	44 Neutral	$69.37M	―	78.44%	―	―	―
MAIA	44 Neutral	$50.81M	―	-459.53%	―	―	62.69%
IMA	41 Neutral	$149.83M	―	-23.76%	―	-100.00%	55.32%
ACRV	36 Underperform	$42.15M	―	-47.87%	―	―	18.86%
ACET	27 Underperform	$59.94M	―	-64.39%	―	―	48.45%